To own Regeneron Pharmaceuticals, you have to believe the core franchises Dupixent and EYLEA HD, plus a wide late stage pipeline, can keep cash flows growing even as older drugs face tougher competition and pricing pressure. The analyst consensus narrative on Simply Wall St leans on that idea, with earnings forecast to rise about 10.6% a year despite slower top line growth than the broader US market.
The near term swing factor is execution on newer launches and label expansions that can offset pressure in retinal disease and any legal or reputational drag from the Libtayo melanoma lawsuits. Livsayis approval strengthens the rare disease story, but it does not change the fact that EYLEA competition and litigation remain the biggest immediate overhangs.
Among the recent updates, the European Commission decision on Libtayo dosing looks most relevant when thinking about Regeneron Pharmaceuticals around the Livsayis launch. Libtayo now offers a less frequent 700 mg every six weeks regimen after an initial period, plus shorter infusion times for some patients, which may support persistence and real world use across skin, lung and cervical cancer indications.
For investors, this feeds into the same execution question that Livsayis raises: can Regeneron convert scientific assets into durable usage in competitive markets while managing safety, boxed warnings and complex treatment logistics? If Libtayo’s more flexible schedule improves adoption or stickiness, it could soften oncology risk and give the business a little more room to absorb EYLEA pressure and fund high cost programs in obesity, siRNA and gene based therapies.
Regeneron Pharmaceuticals’ current earnings are about US$4.8b, with analysts forecasting consensus earnings of US$7.7b by 2029. That implies revenue of roughly US$23.0b and calls for around 10.8% yearly top line growth, with earnings rising by about US$2.9b over that period.
Uncover why Regeneron Pharmaceuticals' fair value indicates a 3% potential upside to its current price that may not last much longer.
One alternate view focuses less on Livsayis and more on trial risk in the broader C5 siRNA platform. The most cautious analysts worried that a tricky transfusion avoidance endpoint in paroxysmal nocturnal hemoglobinuria could cap future rare disease earnings, which is why they were only penciling in about US$19.7b of revenue and US$6.9b of profit by 2029. Those estimates were set before the Livsayis approval. As a result, you now get a live case study in how quickly expectations and narratives can shift.
Explore 4 other Regeneron Pharmaceuticals fair value estimates, including one that suggests as much as 11% downside from the current price.
Disagree with existing narratives? Extraordinary investment performance rarely comes from following the herd, so consider your own analysis.
If the Livsayis story has you thinking about how to balance potential upside with risk, the next step is widening your watchlist. The Simply Wall St Screener lets you quickly sort through opportunities that fit your own return and risk preferences instead of relying on a single stock like Regeneron Pharmaceuticals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com